Sensus Healthcare, Inc. Stock News

Full-service medical oncology practice to pioneer the use of SRT to treat companion animals for both home and veterinary clinic visits

This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer's request. The agreement with the new customer remains in effect.

Sensus Healthcare's Q3 results exceeded expectations with 127% YoY revenue growth and EPS of $0.07, showcasing strong demand recovery and effective management strategies. The Fair Deal Agreement and new FDA contracts, including a major deal with Platinum Dermatology, promise recurring revenue and reduced client concentration risk. Despite impressive financial performance, the stock saw minimal ...

Sensus Healthcare, Inc. (SRTS) Q3 2024 Earnings Call Transcript

Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Signed a Fair Deal Agreement with Platinum Dermatology, a leading dermatology network with 130 clinics across the U.S. Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla.

Sensus Healthcare offers equipment for skin problems, with strong demand but vulnerable to economic instability. The company is recovering in 2024, with initiatives for recurring revenue to improve income stability through software and maintenance services. It has begun its expansion to Asia, which in the future could mitigate the risk of customer concentration.

Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA, IR Joseph Sardano - Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Jason Wittes - ROTH Anthony Vendetti - Maxim Group Eduardo Martinez-Montes - H.C. Wainwright & Co. Operator Good day and w...

Revenues of $9.2 million compares with $4.5 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $2.1 million compares with negative $1.0 million a year ago “Fair Deal Agreement” recurring revenue program gaining momentum with 15 agreements signed to date Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla.